IGF-1R

IGF-1R Inhibitor-5 is a selective inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC50 of 6 μM. This compound exhibits significant potential in cancer research by modulating IGF-1R signaling pathways, which are implicated in various malignancies. Its application may provide insights into tumor growth and progression mechanisms, making it a valuable tool for studies in oncology.

IGF-1R inhibitor-4 is a potent inhibitor of insulin-like growth factor 1 receptor (IGF-1R), demonstrating an inhibition rate of 63% at a concentration of 10 μM. This compound is valuable in cancer research, as it interferes with IGF-1 signaling pathways that contribute to tumor cell proliferation and survival. Researchers can utilize IGF-1R inhibitor-4 to explore therapeutic strategies targeting IGF-1R in various malignancies.

BMS 695735 is a potent inhibitor of the insulin-like growth factor 1 receptor (IGF-1R), exhibiting an IC50 of 0.034 μM. This compound demonstrates significant anti-tumor activity, making it a valuable tool for cancer research. It is suitable for studies investigating IGF-1R's role in tumorigenesis and for assessing potential therapeutic interventions targeting this receptor.

Ceritinib mesylate is a selective ALK tyrosine kinase inhibitor that functions through ATP-competitive mechanisms, exhibiting an IC50 of 200 pM. In addition to its activity against ALK, Ceritinib mesylate also inhibits IGF-1R, InsR, and STK22D, with IC50 values of 8 nM, 7 nM, and 23 nM, respectively. This compound demonstrates significant antitumor potency, making it a valuable tool for research in cancer biology and targeted therapies.